$IMMP News

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA

Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026

Immutep's Abstract On IMP761 Accepted For Poster Presentation At ACR Convergence 2026

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

Immutep Receives A$652,248 Grant From Monash University Under Australian Research Council's Linkage Projects Scheme For Research Collaboration

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive Program

Change to American Depositary Share Ratio

Immutep Changes ADS Ratio From One ADS Representing 10 Shares To One ADS Representing 200 Shares, Effective September 28

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

Immutep Quarterly Activities Report Q4 FY26

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

Immutep Announces Positive Update For Phase I Trial Evaluation Of Eftilagimod Alfa

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Immutep To Present Interim Phase I Data For IMP761 At EULAR 2026

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans?